FDA Approves Adhansia XR

Topics: Adhansia XR | ADHD | adolescents | Attention Deficit Hyperactivity Disorder | Child Psychiatry | children | extended-release | methylphenidate | News of Note | pediatric | teens | treatment

We are always in need of a new formulation of stimulant medication that might capture a few more of our patients who just do not quite tolerate or respond well enough to the many existing formulations. So whenever a new one is released, we try to set aside our natural skepticism and take a look at the stated facts before judging its merit. Adhansia X

In Brief: A 16-Hour Ritalin

Topics: Adhansia XR | Adult ADHD | Ritalin

Adhansia XR is a new extended-release methylphenidate. Its distinguishing feature is its 16-hour duration, which breaks the previous record of 12 hours set by Concerta, Cotempla, Aptensio, and Quillivant. In that respect it is similar to Mydayis, the 16-hour version of Adderall. Adhansia XR releases 20% of its methylphenidate through instant-release b